Man Group
KALV

Man Group’s KalVista Pharmaceuticals KALV Stock Holding History

Man Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$857K Buy
42,576
+25,130
+144% +$405K ﹤0.01% 1891
2025
Q4 		$282K Buy
+17,446
New +$231K ﹤0.01% 2039
2019
Q3 		– Sell
-9,381
Closed -$208K – 1849
2019
Q2 		$208K Hold
9,381
– – ﹤0.01% 1802
2019
Q1 		$268K Buy
+9,381
New +$203K ﹤0.01% 1831

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Man Group's KALV Position: Q1 2026 in Review

Man Group increased its KalVista Pharmaceuticals (KALV) stake by 144% in Q1 2026, buying an estimated $405K and bringing the position to 42,576 shares worth $857K. The position accounts for ﹤0.01% of the portfolio, ranked #1891.

Man Group first reported a position in KALV in Q1 2019 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Man Group held 42,576 shares of KalVista Pharmaceuticals worth $857K as of Q1 2026.
  • Man Group bought 25,130 KalVista Pharmaceuticals shares in Q1 2026, an estimated $405K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #1891 holding.
  • Man Group first reported a position in KalVista Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.